Study Suggests Apitegromab May Preserve Muscle Mass During GLP-1 Weight Loss Treatment
A phase 2 clinical trial published in Nature Medicine found that apitegromab, a drug that blocks a muscle-limiting protein, may help preserve lean body mass in patients taking tirzepatide for weight loss. GLP-1 receptor agonists like tirzepatide are widely used weight loss medications but can result in loss of muscle along with fat. The findings could improve weight loss outcomes by maintaining muscle mass, which is important for metabolism and overall health.
Researchers conducting a phase 2 clinical trial discovered that apitegromab may help prevent muscle loss in patients using tirzepatide, a GLP-1 receptor agonist commonly prescribed for weight loss. The study, published in Nature Medicine, examined whether blocking a protein that naturally limits muscle growth could mitigate the loss of lean body mass that often accompanies weight loss medications. While GLP-1 drugs like tirzepatide are effective for weight reduction, they can result in loss of muscle tissue alongside fat loss, which can negatively affect metabolism and physical function. The findings suggest that combining apitegromab with tirzepatide could improve overall weight loss outcomes by preserving muscle mass. However, this was a phase 2 trial, meaning further research is needed before the treatment could become widely available.
What's missing
The article does not specify the trial's sample size, patient demographics, or specific results (percentage of muscle mass preserved). Additionally, no information is provided about apitegromab's side effects, cost, or timeline for potential FDA approval.
How coverage differed
Only one source was provided, limiting ability to assess differential framing. Medical Xpress presented the findings neutrally as preliminary research suggesting potential benefits without overstating clinical significance.
What different sources said
- Medical XpressCenter
Drug apitegromab may stop muscle loss when taking weight loss drugs
Related
Meta-analysis finds depressive mood sharpens self-judgment while impairing social perception
A large meta-analysis found that depressive mood affects different types of judgment differently—enhancing self-focused judgment while impairing the ability to read social cues. The study, conducted by researchers at Lingnan University, analyzed the relationship between depressive mood and reality judgment across multiple studies. This distinction matters because it challenges the assumption that depression uniformly distorts all judgment and suggests more nuanced cognitive effects.
Study Examines How Extreme Heat Impacts Cancer Care Decisions in South Florida
A new study reveals that extreme heat in South Florida significantly influences how people with cancer manage their daily care and treatment decisions. The research highlights how environmental factors like heat create additional health burdens beyond cancer itself for patients in the region. Understanding these connections is important for developing more comprehensive cancer care strategies that account for climate and environmental stressors.
Consumer Reports Releases 2025 Sunscreen Recommendations After Testing 51 Products
Consumer Reports lab-tested 51 sunscreens and released its top recommendations for 2025, with Coppertone Water Babies lotion SPF 50 ranking as the best overall option. The testing evaluated both chemical and mineral sunscreens, with lotion formulations preferred over sprays due to better visibility of application amounts. The findings emphasize year-round sunscreen use and proper application techniques to maximize UV protection.